DOI: http://dx.doi.org/10.18203/2394-6040.ijcmph20182450

Substance abuse and its psychiatric effect on adolescence

Badr Alghamdi, Mohammed Zrari, Alaa Elahi, Meshari Alwagdani, Eman Alghamdi, Hashem Moafa, Shaher Miran, Shahad Alamoudi, Khaled Alshahrani, Mohammed Binnwejim, Marwan Jaafari

Abstract


Substance abuse amongst adolescence is a widespread health issue that witnesses a progressive increase over years. Substance abuse among this age group is associated with significant psychiatric morbidities that differ according to the substance used. Many literature studies were conducted to explore the psychiatric conditions and consequences associated with substance abuse. To date, cannabis was the most common substance studied and the most well-known illicit drug to be associated with various psychiatric co-morbidities. Other studied substances include alcohol, opiates, barbiturates, hallucinogens, and inhalants. The psychiatric effects of various substances depend on the state, the duration, and the dose of their use. This article will review and discuss the short-term and long-term effects of these substances on the mental health among adolescence.


Keywords


Adolescence, Psychiatric effects, Substance abuse

Full Text:

PDF

References


Measham F, Wood DM, Dargan PI, Moore K. The rise in legal highs: Prevalence and patterns in the use of illegal drugs and first- and second-generation “legal highs” in South London gay dance clubs. J Subst Use. 2011;16(4):263-72.

May PA. Substance abuse and American Indians: Prevalence and susceptibility. Subst Use Misuse. 1982;17(7):1185-209.

Vazan P, Golub A, Bennett AS. Substance use and other mental health disorders among veterans returning to the inner city: Prevalence, correlates, and rates of unmet treatment need. Subst Use Misuse. 2013;48(10):880-93.

Beer MD. Cannabis and mental health. J Psychiatr Intensive Care. 2007;3(1):45-7.

Lipkus IM, Barefoot JC, Williams RB, Siegler IC. Personality Measures as Predictors of Smoking Initiation and Cessation in the UNC Alumni Heart Study. Heal Psychol. 1994;13(2):149-55.

Castaneto MS, Gorelick DA, Desrosiers NA, Hartman RL, Pirard S, Huestis MA. Synthetic cannabinoids: Epidemiology, pharmacodynamics, and clinical implications. Drug Alcohol Depend. 2014;144:12-41.

Macleod J, Hickman M, Smith GD. Early Exposure to Marijuana and Risk of Later Drug Use Early Exposure to Marijuana and Risk of Later Drug Use. JAMA. 2003;290(3):329.

Andréasson S, Engström A, Allebeck P, Rydberg U. Cannabis and Schizophrenia A Longitudinal Study of Swedish Conscripts. Lancet. 1987;330(8574):1483-6.

Arseneault L, Cannon M, Poulton R, Murray R, Caspi A, Moffitt TE. Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. BMJ. 2002;325(7374):1212-3.

Jablensky A, Sartorius N, Ernberg G, Anker M, Korten A, Cooper JE, et al. Schizophrenia - Manifestations, Incidence and Course in Different Cultures - a World-Health-Organization 10-Country Study. Psychol Med Monogr Suppl. 1992;20:1-97.

Jablensky A. Epidemiology of schizophrenia: The global burden of disease and disability. Eur Arch Psychiatry Clin Neurosci. 2000;250(6):274-85.

Lynskey M, Lukas SE, Kranzler HR, Ciraulo DA, Kranzler HR (Ed.., Ciraulo DA (Ed.. Cannabis. Clin Man Addict Psychopharmacol. 2005: 163-181.

Fergusson DM, Lynskey MT, Horwood LJ. The short-term consequences of early onset cannabis use. J Abnorm Child Psychol. 1996;24(4):499-512.

Fergusson DM, Horwood LJ. Early onset cannabis use and psychosocial adjustment in young adults. Addiction. 1997;92(3):279-96.

Brook JS, Cohen P, Brook DW. Longitudinal study of co-occurring psychiatric disorders and substance use. J Am Acad Child Adolesc Psychiatry. 1998;37(3):322-330.

McGee R, Williams S, Poulton R, Moffitt T. A longitudinal study of cannabis use and mental health from adolescence to early adulthood. Addiction. 2000;95(4):491-503.

Patton GC, Harris R, Carlin JB, et al. Adolescent suicidal behaviours: a population-based study of risk. Psychol Med. 1997;27(3):715-24.

Patton GC, Coffey C, Carlin JB, Degenhardt L, Lynskey M, Hall W. Cannabis use and mental health in young people: cohort study. BMJ. 2002;325(7374):1195-8.

Van Os J, Bak M, Hanssen M, Bijl RV, De Graaf R, Verdoux H. Cannabis use and psychosis: A longitudinal population-based study. Am J Epidemiol. 2002;156(4):319-27.

Fergusson DM, Horwood LJ, Swain-Campbell N. Cannabis use and psychosocial adjustment in adolescence and young adulthood. Addiction. 2002;97(9):1123-35.

Grayson M. Cannabis. Nature. 2015;525(7570):S1.

Kumra S. Schizophrenia and cannabis use. Minn Med. 2007;90(1):36-8.

Mariani JJ, Levin FR. Cannabis. In: Clinical Manual of Addiction Psychopharmacology (2nd Ed.).; 2014: 137-170.

Lynskey M, Hall W. The effects of adolescent cannabis use on educational attainment: A review. Addiction. 2000;95(11):1621-30.

Healey JC, Winder DG, Kash TL. Chronic ethanol exposure leads to divergent control of dopaminergic synapses in distinct target regions. Alcohol. 2008;42(3):179-90.

National Institute on Alcohol Abuse and Alcoholism. Health risks and benefits of alcohol consumption. J Natl Inst Alcohol Abus Alcohol. 2000;24(1):5-11.

Vonghia L, Leggio L, Ferrulli A, Bertini M, Gasbarrini G, Addolorato G. Acute alcohol intoxication. Eur J Intern Med. 2008;19(8):561-7.

Huang B. Methanol intoxication. In: Brain Imaging with MRI and CT: An Image Pattern Approach; 2010: 11-12.

Nobay F, Acquisto NM. Barbiturates. In: Wexler, P. (Ed.). Encyclopedia of Toxicology. 3rd edition. Vol 1. Elsevier Inc., Academic Press; 2014; 363-367.

Grasso I, Distefano A, Azzolina R. Barbiturates poisoning. Acta Medica Mediterr. 2003;19(3):189-90.

Cruz SL, Granados-Soto V. Opioids and opiates: Pharmacology, abuse, and addiction. In: Neuroscience in the 21st Century: From Basic to Clinical, Second Edition. 2016: 3625-3657.

Lichtermann D, Franke P, Maier W, Rao ML. Pharmacogenomics and addiction to opiates. Eur J Pharmacol. 2000;410(2-3):269-79.

Warsi M, Marcil W, Petty F. Hallucinogen abuse. In: XPharm: The Comprehensive Pharmacology Reference. 2011: 1-7.

Hermle L, Simon M, Ruchsow M, Geppert M. Hallucinogen-persisting perception disorder. Ther Adv Psychopharmacol. 2012;2(5):199-205.